biomarkers

In the rapidly evolving field of cancer research, understanding the complex interplay between tumors and the immune system is essential for developing effective therapies. Bio-Plex Multiplex Immunoassays, for research use only and powered by Luminex xMAP technology, provide a cutting-edge tool for simultaneously measuring multiple immune biomarkers. Learn how these research tools are paving the way for development of personalized cancer treatments in the future.

Estrogen receptor 1 (ESR1) mutations in breast tumors were first identified nearly 30 years ago. Since then, technology has evolved, as has our understanding of the impact these mutations have on tumor cell physiology. Given the dynamic nature of ESR1 mutation acquisition and enrichment, ctDNA samples appear to be the most robust source for analysis. Droplet Digital PCR (ddPCR) enables rapid, highly sensitive, cost-effective analysis of ctDNA, providing a powerful tool for this critical area of cancer research.

In nature, mammalian extracellular vesicles (EVs) are vital for intercellular communication, immune responses, and cell removal. EVs also hold promise in diagnostics, therapeutics, and vaccine delivery due to their abundance and natural role as carriers. Explore how overcoming challenges in EV purification and precise RNA analysis methods can help unlock their potential applications.

Astrid Irwanto is the co-founder and COO of NalaGenetics, a company taking a novel, personalized approach to understanding genetic susceptibility to drug reactions in Southeast Asian populations. A PhD in human genetics and postdoctoral research in genetics disease, along with personal experiences, fuel Astrid’s pursuits. In this interview, we discuss NalaGenetics’ approach to pharmacogenomics and why Astrid decided to translate her academic research to a molecular diagnostics company.

As the third most prevalent cancer worldwide, colorectal cancer (CRC) is a significant global health burden. Biomarker identification and detection has proven a powerful strategy for improving CRC diagnosis and informing targeted treatment. Microsatellite instability (MSI) is a key biomarker in CRC, and with Droplet Digital PCR (ddPCR), MSI can be accurately detected using a wider range of sample types.

Historically, five-year survival rates have been used to evaluate cancer therapeutic effectiveness in clinical trials. But time is critical for research — and for patients. Fortunately, there is a promising method for evaluating cancer therapeutic effectiveness that could potentially offer prognostic insights after just one year. Noninvasive liquid biopsy analysis, including analysis of circulating tumor DNA, is improving researchers’ ability to detect clinical responses more rapidly.

Cancer remains a leading cause of death worldwide. However, as cancer treatments continue to improve and diagnoses happen sooner, more and more patients are experiencing remission. To further increase survival rates and reduce unnecessary treatment, scientists and clinicians are turning to ultra-sensitive molecular analysis to inform treatment decisions and predict and detect relapse.

Frost & Sullivan, a business consulting firm involved in market research and analysis, conducted a thought leadership forum that brought together experts in the field of immuno-oncology. Follow their discussions about the current state of immunotherapies and the key challenges and future approaches to the targeted use of the immune system in cancer treatment.

Frost & Sullivan, a business consulting firm involved in market research and analysis, conducted a thought leadership forum that brought together experts in the field of CNS biomarkers. Follow their discussions about technological advancements in the field and future implications of the current research and development.

For the past 30 years, there has been one assumed culprit of Alzheimer’s disease (AD) — beta-amyloid. However, researchers have been unsuccessful in developing effective therapies targeting this protein. Understand the history of AD and beta-amyloid and see what other biomarkers are being investigated as potential therapeutic targets.